Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals announced its Q4 2020 financial results and provided a pipeline update. As of December 31, 2020, the company held $293.1 million in cash and reported a net loss of $20.4 million ($0.44 per share) for the quarter. Research and development expenses for the quarter rose to $15.5 million from $9.5 million, driven by increased clinical activities. The company expects R&D expenses to reach $90 to $100 million in 2021. Key milestones include the Phase 1 data presentation for SNDX-5613 and the initiation of the pivotal Phase 2 AGAVE-201 trial for axatilimab.
- Cash reserves of $293.1 million as of December 31, 2020.
- Initiation of the pivotal Phase 2 AGAVE-201 trial for axatilimab.
- Plans to present Phase 1 data for SNDX-5613 in Q2 2021.
- Net loss increased to $20.4 million in Q4 2020 from $14.0 million year-over-year.
- Research and development expenses rose to $15.5 million in Q4 2020, indicating higher costs.
WALTHAM, Mass., March 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2020. In addition, the Company provided a clinical and business update.
"We expect 2021 will be a year of immense progress across our two highly promising programs aimed at addressing key areas of unmet need, coupled with a sharp focus on pipeline expansion," said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. "Notably, we plan to present data from the Phase 1 portion of our ongoing AUGMENT-101 trial of SNDX-5613, our selective menin inhibitor, in patients with acute leukemias. We presented promising initial clinical data at the 2020 AACR Annual Meeting that provided the first clinical evidence that disrupting the interaction between menin and MLL1 can induce rapid responses in difficult to treat acute leukemias. We look forward to sharing updated results which further expand on SNDX-5613's potential to meaningfully alter the treatment paradigm in genetically-defined acute leukemias."
"Additionally, on the heels of positive data presented at the ASH Annual Meeting in December from our Phase 1 trial of axatilimab, our anti-CSF-1R monoclonal antibody, in patients with cGVHD, we are pleased to announce that our pivotal Phase 2 AGAVE-101 trial is now underway. Through inhibition of monocyte derived macrophages, axatilimab has demonstrated important clinical benefits in multiple organ systems. We believe axatilimab could represent a meaningful therapeutic option for additional fibrotic diseases where macrophages have been shown to play a significant role, and we are actively exploring additional indications."
Recent Progress and Anticipated Milestones
SNDX-5613
Syndax plans to share data from the Phase 1 AUGMENT-101 trial of SNDX-5613, its highly selective, oral menin inhibitor, in patients with mixed lineage leukemia rearranged (MLL-r) and nucleophosmin (NPM1) mutant acute leukemias late in the first quarter or early in the second quarter of 2021. Additional details regarding the presentation, which will feature the trial's principal investigator, Eytan M. Stein, M.D. Assistant Attending Physician and Director, Program for Drug Development in Leukemia, Department of Medicine at Memorial Sloan Kettering Cancer Center, will be announced in the coming weeks. The Company remains on track to initiate the Phase 2 portion of the trial in the second quarter of 2021, which could potentially serve as the basis for a regulatory filing.
Axatilimab
At the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December 2020, Syndax reported updated data from its Phase 1 trial of axatilimab, its anti-CSF-1R monoclonal antibody, in patients with chronic graft versus host disease (cGVHD). Data demonstrated deep, durable responses and multiorgan clinical benefit in patients refractory to multiple therapeutic agents.
The Company announced today that the pivotal Phase 2 AGAVE-201 trial, which will evaluate the safety and efficacy of three doses and schedules of axatilimab in patients with cGVHD, began enrolling patients earlier this quarter. The primary endpoint will assess objective response rate based on the 2014 NIH consensus criteria for GVHD, with key secondary endpoints including duration of response and improvement in modified Lee Symptom Scale score. The Company expects to report topline data in 2023.
Fourth Quarter 2020 Financial Results
As of December 31, 2020, Syndax had cash, cash equivalents and short-term investments of
Fourth quarter 2020 research and development expenses increased to
General and administrative expenses for the fourth quarter 2020 decreased to
For the three months ended December 31, 2020, Syndax reported a net loss attributable to common stockholders of
Financial Update and Guidance
In December 2020, Syndax issued 6,250,000 shares of its common stock at
For the first quarter of 2021, research and development expenses are expected to be
Conference Call and Webcast
In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET today, Monday, March 8, 2021.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:
Conference ID: 7949816
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast: https://edge.media-server.com/mmc/p/wdaqmgg3
For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Investors section of the Company's website, www.syndax.com.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.
Syndax's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "believe" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, the potential use of our product candidates to treat various cancer indications, Syndax's fourth quarter and full-year 2020 net cash used in research and development and total operating activities, and first quarter and full year 2021 operating expense and cash guidance. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity, failure of Syndax's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842
SNDX-G
SYNDAX PHARMACEUTICALS, INC. | ||||||||||
(unaudited) | ||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||
December 31, | ||||||||||
(In thousands) | 2020 | 2019 | ||||||||
Cash, cash equivalents and short-term investments | $ 293,065 | $ 59,775 | ||||||||
Total assets | $ 300,613 | $ 63,525 | ||||||||
Total liabilities | $ 48,425 | $ 31,925 | ||||||||
Total stockholders' equity (deficit) | $ 252,188 | $ 31,600 | ||||||||
Common stock outstanding | 47,881,223 | 27,140,484 | ||||||||
Common stock and common stock equivalents* | 57,836,910 | 42,292,534 | ||||||||
*Common stock and common stock equivalents: | ||||||||||
Common stock | 47,881,223 | 27,140,484 | ||||||||
Options to purchase common stock | 6,379,235 | 6,057,011 | ||||||||
Restricted Stock Units | 18,500 | - | ||||||||
Series 1 and 2 warrants | - | 4,595,039 | ||||||||
Pre-funded warrants | 3,557,952 | 4,500,000 | ||||||||
57,836,910 | 42,292,534 | |||||||||
SYNDAX PHARMACEUTICALS, INC. | ||||||||||
(unaudited) | ||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||
Three Months Ended December 31, | Year Ended December 31, | |||||||||
(In thousands, except share and per share data) | 2020 | 2019 | 2020 | 2019 | ||||||
License fee revenue | $ 380 | $ 380 | $ 1,517 | $ 1,517 | ||||||
Operating expenses: | ||||||||||
Research and development | 15,522 | 9,502 | 50,435 | 42,994 | ||||||
General and administrative | 4,718 | 5,083 | 22,505 | 16,062 | ||||||
Total operating expenses | 20,240 | 14,585 | 72,940 | 59,056 | ||||||
Loss from operations | (19,860) | (14,205) | (71,423) | (57,539) | ||||||
Other income (expense), net | (563) | 205 | (1,735) | 1,492 | ||||||
Net loss | $ (20,423) | $ (14,000) | $ (73,158) | $ (56,047) | ||||||
Net loss attributable to common stockholders | $ (20,423) | $ (14,000) | $ (77,064) | $ (56,047) | ||||||
Net loss per share attributable to common | ||||||||||
stockholders--basic and diluted | $ (0.44) | $ (0.44) | $ (1.87) | $ (1.84) | ||||||
Weighted-average number of common stock | ||||||||||
used to compute net loss per share attributable | ||||||||||
to common stockholders--basic and diluted | 46,054,850 | 31,640,484 | 41,308,242 | 30,490,783 | ||||||
View original content:http://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-fourth-quarter-2020-financial-results-and-provides-clinical-and-business-update-301242684.html
SOURCE Syndax Pharmaceuticals, Inc.
